RxDoctor Payments Data

Javier Morales, MD

Infectious Disease · San Juan, PRNPI 1346231040

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,980 of the $8,978 with a category attached, or 77.7%. 9 manufacturers reported payments, led by Merck at 56.5% of the total. Reporting peaked in 2019 at $5,472 and has fallen 99.2% since, to $45 in 2025.

$8,978in general payments, 2019–2025

Across 23 payments — averaging $390.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5K
  • Viiv Healthcare Company$4K
  • Boston Scientific$42
  • Janssen Products, LP$30
  • Boehringer Ingelheim$27
  • Johnson & Johnson$26
  • plus $69 from 3 others
$5,876,723in research payments, 2019–2025

Across 1,114 payments — averaging $5275.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$1.8M
  • Modernatx, Inc.$962K
  • Viiv Healthcare Company$833K
  • Sanofi Pasteur Inc.$801K
  • AbbVie$539K
  • Gilead$417K
  • plus $481K from 5 others

What the payments were for

  • Consulting fees$6,98078%
  • Speaking & faculty fees$1,12513%
  • Travel & lodging$1542%
  • Food & beverage$6778%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,978 in reported general payments places this provider in the 85th percentile of 127 infectious disease providers in Puerto Rico.

See all infectious disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$5,213
Medicare patients
29
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala110$472,429
TivicayDolutegravir Sodium132$382,339
DescovyEmtricitabine/Tenofov Alafenam90$209,192
DovatoDolutegravir Sodium/Lamivudine17$51,589
PrezistaDarunavir12$34,110
AptivusTipranavir12$24,820
VemlidyTenofovir Alafenamide14$20,268
Etravirine15$17,636
Efavirenz19$12,722
Ritonavir69$6,771
Darunavir29$6,415
Lamivudine20$1,513
ValacyclovirValacyclovir Hcl28$840
Tenofovir Disoproxil Fumarate13$641
Rosuvastatin Calcium31$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Vemlidy$23$701,889214 claims
Viiv Healthcare CompanyTivicay, Dovato$3,714$433,928149 claims
Boehringer IngelheimAptivus$27$24,82012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 infectious disease providers in Puerto Rico.

Other infectious disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →